To view enhanced content for this article go to http://www.medengine.com/Redeem/CD08F0601C9691C1.
Oral anticoagulant therapy, such as vitamin K antagonists (VKAs), is prominent for the prevention of cerebral ischemic stroke or systemic embolism and all-cause mortality in patients with atrial fibrillation, venous thromboembolism, and mechanical or biological valve. VKA treatment requires monitoring of the international normalized ratio (INR) in order to maintain it in a therapeutic range, avoiding side effects, the main and most significant of which is bleeding. The aim of the present study was to evaluate the event rates of several clinical composite outcomes, such as bleeding, thromboembolic events, and all-cause death.
We compared three organizational models distinguished by a total (from 1 January to 31 December 2015 in which PT/INR analysis with the relative internal and external quality controls was performed by the surveillance center) or partial (from 15 January to 15 July 2016 and from 15 August to 15 November 2016, in which the surveillance center had the ability to view only the PT/INR results or all patients analyses, including blood count, creatinine, liver enzymes, etc., respectively) analytical patient management. The present longitudinal follow-up study included 1225 patients, recruited from 1 January 2015 to 15 November 2016 at a surveillance center for the prevention of cerebral ischemic stroke and systemic embolism in Chieti (Italy).
The results show a significant rise of the incidence rate ratio in patients undergoing VKA treatment during the period 15 January to 15 July 2016 compared to the previous one regarding total bleeding, especially for minor bleeding and digestive bleeding; thromboembolic events; and all-death cause.
These findings show that analytical and clinical data and information should be under the direct supervision and responsibility of the surveillance center. In fact, this approach seems to highlight the best results in terms of safety and therapeutic effectiveness.
Wipf JE, Lipsky BA. Atrial fibrillation. Thromboembolic risk and indications for anticoagulation. Arch Int Med. 1990;150:1598–1603.
Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. Br Med J. 2014;348:g2116. CrossRef
Tidjane N, Hachem A, Zaid Y, et al. A primary role for kinin B1 receptor in inflammation, organ damage, and lethal thrombosis in a rat model of septic shock in diabetes. Euro J Inflamm. 2015;13:40–52. CrossRef
Jia XF, Hong Z, Fan JH, Zhang YM. Clinical effect of mechanical fragmentation combined with recombinant tissue plasminogen activator artery thrombolysis on acute cerebral infarction. J Biol Regul Homeost Agents. 2016;30(3):821–6. PubMed
Fang Y, Zong HL, Zhang L, Wang ZH, Sun LM, Zhang RF. Vena-venous hemofiltration in treating severe injury-induced multiple organ dysfunction syndrome. J Biol Regul Homeost Agents. 2016;30(2):477–84. PubMed
Mallouppas M, Vassiliou V. Anticoagulation for atrial fibrillation: is this the end of warfarin? Not just yet. J Angiol. 2013. doi: 10.1155/2013/874827
January CT, Wann LS, Alpert JS. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol. 2014;64:2246–80. CrossRef
CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349(9066):1641–9.
Piotrowska Ż, Janiuk I, Lewandowska A, Kasacka I. Decreased immunoreactivity of visfatin in the pancreas and liver of rats with renovascular hypertension. J Biol Regul Homeost Agents. 2016;30(4):1073–8. PubMed
Crincoli V, Ballini A, Fatone L, Di Bisceglie MB, Nardi GM, Grassi FR. Cytokine genotype distribution in patients with periodontal disease and rheumatoid arthritis or diabetes mellitus. J Biol Regul Homeost Agents. 2016;30(3):863–6. PubMed
Adar T, Edden Y, Shteingart S, et al. Portal hypertension is associated with modulation of regulatory T cells. Eur J Inflamm. 2016;14:40–47.
Rietbrock S, Heeley E, Plumb J. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156:57–64. CrossRefPubMed
Olesen JB, Lip GY, Hansen ML. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. Br Med J. 2011;342:d124. CrossRef
Arbring K, Uppugunduri S, Lindhal TL. Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics. BMC Health Serv Res. 2013;7(13):85. CrossRef
Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J. 2011;32(18):2282–9.
Wysowski DK, Nourjah P. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Int Med. 2007;167:1414–9. CrossRef
Chow S, Shao J, Wang H. Sample size calculations in clinical research, 2nd ed. Boca Raton: Chapman & Hall/CRC Biostatistic Series.
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4. CrossRefPubMed
Chuai JB, Shi L, Ma XY, Wu D, Kang K, Jiang SL. Curative effect of mechanical heart valve replacement and anticoagulant therapy after surgery. J Biol Regul Homeost Agents. 2016;30(1):141–6. PubMed
Yang F, Xiang ML, Liu YM. Thrombin in combination with intensive nursing in treating upper gastrointestinal bleeding in children. J Biol Regul Homeost Agents. 2016;30(2):491–5. PubMed
- Analytical Management of Patients Undergoing Oral Anticoagulant Therapy Could Have a Strong Impact on Clinical Outcomes: A Follow-up Study
Vincenzo De Iuliis
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II